Pasi Janne
机构: Dana Farber Cancer Institute
每年引用次数
引用次数
引用: 134,728
H-指数: 163
I10-指数 : 547
出版物: 1,257
Gefitinib Birinci mi Yoksa‹ kinci mi?
PASI A JÄNNE
Am J Respir Crit Care Med 178 558 -564
2008
Novel agents in the treatment of lung cancer
Thomas J LYNCH , Pasi A JÄNNE , Sarada GURUBHAGAVATULA
Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer.
Bruce E. Johnson , R. Ilona Linnoila , Pasi A. Jänne , Melissa Means-Markwell
Clinical Cancer Research 9 ( 16) 5915 -5921
2
2003
A New Device for Rapid Isolation by Size and Characterization of Rare Circulating Tumor Cells
Robert J. Distel , Bella S. Guerrouahen , Masahiko Yanagita , Yvon E. Cayre
Anticancer Research 31 ( 2) 427 -441
294
2011
Histology... For want of anything better
Pasi A. Jänne , Alexis B. Cortot
Oncology 23 ( 13) 1140 -1141
1
2009
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.
Chiara Ambrogio , Chiara Ambrogio , Ramon V. Tiu , Atsuko Ogino
Molecular Cancer Therapeutics 20 ( 4) 641 -654
1
2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC
Geoffrey R. Oxnard , Jonathan W. Riess , Penelope A. Bradbury , Michael L. Cheng
JCO Precision Oncology ( 5) 393 -402
2021
Overcoming therapy resistance in EGFR -mutant lung cancer
Tony Mok , Antonio Passaro , Solange Peters , Pasi A. Jänne
Nature Cancer 2 ( 4) 377 -391
90
2021
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC
Lynette M. Sholl , Lynette M. Sholl , Biagio Ricciuti , Mark M. Awad
JCO Precision Oncology ( 5) 726 -732
2021
Kinase drug discovery 20 years after imatinib: progress and future directions.
Philip Cohen , Darren Cross , Pasi A. Jänne
Nature Reviews Drug Discovery 1 -19
294
2021
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Suresh S Ramalingam , James C-H Yang , Chee Khoon Lee , Takayasu Kurata
Journal of Clinical Oncology 36 ( 9) 841 -849
244
2018
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
David Jackman , William Pao , Gregory J. Riely , Jeffrey A. Engelman
Journal of Clinical Oncology 28 ( 2) 357 -360
892
2010
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Steffen Boettcher , Peter G Miller , Rohan Sharma , Marie McConkey
Science 365 ( 6453) 599 -604
217
2019
RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
Mizuki Nishino , Stephanie Cardarella , David M. Jackman , Nikhil H. Ramaiya
American Journal of Roentgenology 201 ( 1)
29
2013
Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
Myung‐Ju Ahn , Chun‐Ming Tsai , Frances A. Shepherd , Lyudmila Bazhenova
Cancer 125 ( 6) 892 -901
54
2019
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease
Luca Toschi , Giovanna Finocchiaro , Teresa T. Nguyen , Margaret C. Skokan
PLOS ONE 9 ( 4) 1 -7
67
2014
Mapping of the 75-kDa inositol polyphosphate-5-phosphatase (Inpp5b) to distal mouse chromosome 4 and its exclusion as a candidate gene for dysgenetic lens.
Pasi A. Jänne , Julie M. Rochelle , Patricia A. Martin-DeLeon , Dwight Stambolian
Genomics 28 ( 2) 280 -285
7
1995
Circulating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation?
Valentin Haug , Yanan Kuang , Sotirios Tasigiorgos , Branislav Kollar
Transplantation 104 ( 3)
2
2020
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke , Kreshnik Zejnullahu , Yi-Long Wu , Youngchul Song
Cancer Cell 17 ( 1) 77 -88
797
2010
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Peter C. Lo , Suzanne E. Dahlberg , Mizuki Nishino , Bruce E. Johnson
Cancer 121 ( 15) 2570 -2577
32
2015